1. Chua EW, Kennedy MA. Current state and future prospects of direct-to-consumer Pharmacogenetics. Front Pharmacol. 2012;3:152.
2. Rasmussen-Torvik LJ, Stallings SC, Gordon AS, Almoguera B, Basford MA, Bielinski SJ, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther. 2014;96:482–9.
3. Burton A. Are we ready for direct-to-consumer genetic testing? Lancet Neurol. 2015;14:138–9.
4. Dandekar S, Chang E, Hromatka B, Chubb A, Wu S. Guidelines on Vetting and Reporting Variants with Strong Effects on Health [PDF]. 23andMe; 2014.
https://23andme.https.internapcdn.net/res/pdf/45NSStEUhM8G-e_5JXdTUw_23-07_Vetting_Variants.pdf
. Accessed 9 Dec 2016.
5. Table of Pharmacogenomic Biomarkers in Drug Labeling: U.S. Food and Drug Administration; 2015.
http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm
. Accessed 8 Dec 2016.